411 related articles for article (PubMed ID: 12031892)
21. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.
Ostrerova-Golts N; Petrucelli L; Hardy J; Lee JM; Farer M; Wolozin B
J Neurosci; 2000 Aug; 20(16):6048-54. PubMed ID: 10934254
[TBL] [Abstract][Full Text] [Related]
22. Aggregation and neurotoxicity of alpha-synuclein and related peptides.
el-Agnaf OM; Irvine GB
Biochem Soc Trans; 2002 Aug; 30(4):559-65. PubMed ID: 12196137
[TBL] [Abstract][Full Text] [Related]
23. Metals, oxidative stress and neurodegenerative disorders.
Jomova K; Vondrakova D; Lawson M; Valko M
Mol Cell Biochem; 2010 Dec; 345(1-2):91-104. PubMed ID: 20730621
[TBL] [Abstract][Full Text] [Related]
24. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
25. Alzheimer's and Parkinson's disease--overlapping or synergistic pathologies?
Kurosinski P; Guggisberg M; Götz J
Trends Mol Med; 2002 Jan; 8(1):3-5. PubMed ID: 11796255
[TBL] [Abstract][Full Text] [Related]
26. Alpha-synuclein and Parkinson's disease.
Lücking CB; Brice A
Cell Mol Life Sci; 2000 Dec; 57(13-14):1894-908. PubMed ID: 11215516
[TBL] [Abstract][Full Text] [Related]
27. Lewy body variant of Alzheimer's disease: alpha-synuclein in dystrophic neurites of A beta plaques.
Wirths O; Weickert S; Majtenyi K; Havas L; Kahle PJ; Okochi M; Haass C; Multhaup G; Beyreuther K; Bayer TA
Neuroreport; 2000 Nov; 11(17):3737-41. PubMed ID: 11117482
[TBL] [Abstract][Full Text] [Related]
28. Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils.
Bodles AM; Guthrie DJ; Harriott P; Campbell P; Irvine GB
Eur J Biochem; 2000 Apr; 267(8):2186-94. PubMed ID: 10759841
[TBL] [Abstract][Full Text] [Related]
29. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease.
Li J; Zhu M; Manning-Bog AB; Di Monte DA; Fink AL
FASEB J; 2004 Jun; 18(9):962-4. PubMed ID: 15059976
[TBL] [Abstract][Full Text] [Related]
30. Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide.
Jensen PH; Sørensen ES; Petersen TE; Gliemann J; Rasmussen LK
Biochem J; 1995 Aug; 310 ( Pt 1)(Pt 1):91-4. PubMed ID: 7646476
[TBL] [Abstract][Full Text] [Related]
31. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
[TBL] [Abstract][Full Text] [Related]
32. Properties of NACP/alpha-synuclein and its role in Alzheimer's disease.
Iwai A
Biochim Biophys Acta; 2000 Jul; 1502(1):95-109. PubMed ID: 10899435
[TBL] [Abstract][Full Text] [Related]
33. Enhanced oligomerization of the alpha-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system.
Kang JH; Kim KS
Mol Cells; 2003 Feb; 15(1):87-93. PubMed ID: 12661766
[TBL] [Abstract][Full Text] [Related]
34. Alpha-synuclein, Abeta and Alzheimer's disease.
Wirths O; Bayer TA
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):103-8. PubMed ID: 12551731
[TBL] [Abstract][Full Text] [Related]
35. Generation of hydrogen peroxide from mutant forms of the prion protein fragment PrP121-231.
Turnbull S; Tabner BJ; Brown DR; Allsop D
Biochemistry; 2003 Jul; 42(25):7675-81. PubMed ID: 12820876
[TBL] [Abstract][Full Text] [Related]
36. Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro.
Köppen J; Schulze A; Machner L; Wermann M; Eichentopf R; Guthardt M; Hähnel A; Klehm J; Kriegeskorte MC; Hartlage-Rübsamen M; Morawski M; von Hörsten S; Demuth HU; Roßner S; Schilling S
Molecules; 2020 Jan; 25(3):. PubMed ID: 32013170
[TBL] [Abstract][Full Text] [Related]
37. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
[TBL] [Abstract][Full Text] [Related]
38. Novel Benzothiazole Derivatives as Fluorescent Probes for Detection of β-Amyloid and α-Synuclein Aggregates.
Watanabe H; Ono M; Ariyoshi T; Katayanagi R; Saji H
ACS Chem Neurosci; 2017 Aug; 8(8):1656-1662. PubMed ID: 28467708
[TBL] [Abstract][Full Text] [Related]
39. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
40. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease.
Hashimoto M; Takeda A; Hsu LJ; Takenouchi T; Masliah E
J Biol Chem; 1999 Oct; 274(41):28849-52. PubMed ID: 10506125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
